The Indonesia AIDS Coalition (IAC) and Indonesia for Global Justice (IGJ) have filed a patent opposition for the Tuberculosis (TB) drug Bedaquiline with dispersible tablet formulations (hereinafter, in the context of this article, will be referred to as ‘Bedaquiline’). The patent opposition was filed to the Patent Appeal Commission, Directorate General of Intellectual Property (DGIP), Ministry of Law and Human Rights. The patent opposition was submitted in November 2022 and was rejected by a decision from the Judiciary Panel on November 9th, 2023. Read more here.
top of page
Recent Posts
See AllThe results of the TB-CHAMP trial were recently published. They showed that prophylactic levofloxacin can significantly reduce the risk...
190
This month, the Indian Patent Office denied the last of the three Janssen patent extension applications for bedaquiline. While TB...
100
The Institute of Tropical Medicine has announced two initiatives to honor the legacy of Armand Van Deun: a new meeting room in his name...
560
bottom of page
Opmerkingen